DCP Capital, an international private equity firm, and Sequoia Capital China, a VC firm, led a $133m series B funding round in Valgen Medtech, a researcher and developer of minimally invasive medical devices, with participation from Ascendum Capital, China Life Investment Holding Company, Lake Bleu Capital, Qiming Venture Partners, and Venus Medtech. " Leveraging China's rich engineering resources, Valgen developed the first transapical and transcatheter mitral valve products in China, and established its pioneering position in the global structural heart space. The DCP team has a strong 28-year investment track record and has nurtured numerous leaders across many industries in China and we are thrilled to work with them. Following the investment, Valgen will continue to accelerate its R&D and commercialization efforts for our minimally invasive interventional medical devices in the mitral and tricuspid valve area, to provide doctors and patients with innovative treatment solutions," Michael Zhao, Valgen Chairman.